

GESAMTVERZEICHNIS

1

23.11.2009

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.

Quinzler, R.; Ude, M.; Franzmann, A.; Feldt, S.; Leuner, K.; Müller, W.; Dippel, F.; Schulz, M.

ISPOR 12th Annual European Congress, 24.-27.10.2009, Paris, France

Value Health [abstract]. 2009; 12: A234 (DB2)

Conflicts of interest: The DAPI received financial support for this study from Sanofi-Aventis; Dippel F.W. employee Sanofi-Aventis.

2

23.11.2009

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.

Quinzler, R.; Ude, M.; Franzmann, A.; Feldt, S.; Schüssel, K.; Leuner, K.; Müller, W.; Dippel, F.; Schulz, M.

16. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie, 19.-20.11.2009, Berlin, Germany

Düsseldorf: German Medical Science GMS Publishing House; 2009.
Doc09gaa02. DOI: 10.3205/09gaa02, URN: urn:nbn:de:0183-09gaa021

Conflicts of interest: The DAPI received financial support for this study from Sanofi-Aventis; Dippel F.W. employee Sanofi-Aventis.


3

23.11.2009

Pharmacy refill adherence with antidepressants.

Hengstler-Stahl, S.; Leuner, K.; Schüssel, K.; Franzmann, A.; Schulz, M.; Müller, W.

DPhG Jahrestagung, 28.9.-1.10.2009, Jena, Germany

 Hengstler DPhG 2009 - Pharmacy refill adherence with antidepressants

Conflicts of interest: none declared.


4

23.11.2009

Utilizing claims data to assess persistence with antidepressants.

Hengstler-Stahl, S.; Leuner, K.; Schüssel, K.; Franzmann, A.; Schulz, M.; Müller, W.

ESCP-GSASA-Symposium, 3.-6.11.2009, Genf, Switzerland

 Hengstler ESCP 2009 - Utilizing claims data to assess persistence with antidepressants

Conflicts of interest: none declared.


5


01.06.2009

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller, V.; Schüssel, K.; Czeche, S.; Franzmann, A.; Klöckner, D.; Quinzler, R.; Schulz, M.; Möhrke, W.; Hadji, P.

36th European Symposium on Calcified Tissues, 23.-27.5.2009, Vienna, Austria.

 ECTS 2009, Wien; Poster: Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

 Bone 2009; 44 (Suppl. 2): S449 (Abstract P511)

Conflicts of interest: W.Moehrke, Procter and Gamble Pharmaceuticals, Employee; M.Schulz, Procter and Gamble Pharmaceuticals, Grant; P.Hadji, Procter and Gamble Pharmaceuticals, Consultant.

6

30.03.2009

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller, V.; Schüssel, K.; Czeche, S.; Franzmann, A.; Klöckner, D.; Quinzler, R.; Schulz, M.; Möhrke, W.; Hadji, P.

ECCEO 9-IOF, 18.-21.3.2009, Athens, Greece.

Osteoporosis Int. 2009; 20 (Suppl. 1): S112 (Abstract P320).

Conflicts of interest: The DAPI received financial support for this study from Procter and Gamble Pharmaceuticals; Moehrke W. employee Procter and Gamble Pharmaceuticals; Hadji P. consultant for Procter and Gamble Pharmaceuticals.


7

30.03.2009

Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?

Schüssel, K.; Czeche, S.; Franzmann, A.; Klöckner, D.; Quinzler, R.; Schulz, M.; Möhrke, W.; Hadji, P.

Osteologie-Kongress der Deutschen Gesellschaft für Osteologie, 5.-7.3.2009, Frankfurt, Germany

 Schuessel Osteologie 2009

Conflicts of interest: The DAPI received financial support for this study from Procter and Gamble Pharmaceuticals; Moehrke W. employee Procter and Gamble Pharmaceuticals; Hadji P. consultant for Procter and Gamble Pharmaceuticals.



Hinweis: Für die Ansicht der PDF Dokumente wird der Acrobat Reader benötigt. Klicken Sie auf die Grafik, um ihn herunterzuladen.